Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ndovu RCT: DTG vs DRV/r in DTG-resistant HIV
NCT06747507Phase 3Recruiting
- Sponsor
- University of Nairobi
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by University of Nairobi. Primary endpoint: Proportion of participants with HIV-1 RNA of <200 copies/mL at 6 months. Started Sep 2025; status: recruiting.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06747507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747507.